Fortis Healthcare Reports Strong Q1 FY26 Results with 16.6% Revenue Growth and Strategic Expansion
The announcement details strong quarterly financial results, indicating robust operational performance and profitability. The strategic acquisitions and partnerships announced also point towards future growth and market expansion, which are significant for the company's long-term outlook.
The company reported significant year-on-year growth in consolidated revenue (16.6%), operating EBITDA (43.2%), and PAT (56.8%). Both hospital and diagnostic segments demonstrated strong financial performance and margin expansion. Additionally, strategic expansions through an O&M agreement and an acquisition indicate positive future growth prospects.
Fortis Healthcare Limited announced its unaudited consolidated financial results for the quarter ended June 30, 2025, broadcasting the press release and earnings presentation on August 6, 2025. Key highlights include: * Consolidated Revenues stood at ₹2,167 crore, marking a 16.6% year-on-year increase from ₹1,859 crore in Q1 FY25. Operating EBITDA grew by 43.2% to ₹491 crore, with the operating EBITDA margin improving to 22.6% from 18.4% in Q1 FY25. * Profit After Tax (PAT) after Minority Interest and Share in Associates increased by 56.8% to ₹260 crore (excluding exceptional items). * The Hospital Business reported revenues of ₹1,838 crore, up 18.6% year-on-year, and an operating EBITDA margin of 22.1% (versus 18.5% in Q1 FY25). Average Revenue Per Occupied Bed (ARPOB) increased by 10.2% to ₹2.65 crore per annum, and occupancy rose to 69% from 67% in Q1 FY25. International patient revenues grew 21% to ₹154 crore. * The Diagnostic Business (Agilus) recorded gross revenues of ₹368.8 crore, up 7.4% year-on-year, with operating EBITDA margins (basis gross revenues) at 23.0% (versus 16.1% in Q1 FY25). Agilus conducted approximately 10.13 million (~1.013 crore) tests in the quarter and added over 160 new customer touch points. * Fortis expanded its footprint through an Operation and Maintenance Services (O&M Services) agreement with Gleneagles India in July 2025, managing operations of approximately 700 beds across five hospitals and a clinic. The company also completed the acquisition of Shrimann Superspecialty Hospital in Jalandhar, adding 228 beds. * Dr. Ashutosh Raghuvanshi, MD and CEO, commented on the healthy start to the financial year for both hospital and diagnostic businesses, highlighting the strategic O&M agreement and Shrimann acquisition for geographic expansion and operational optimization. He also noted the strong recovery in diagnostics revenues and EBITDA margins, expecting the growth momentum to continue.
What to do with a filing like this
Fortis Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fortis Healthcare Limited. Read the original for the full detail.